HC Wainwright Predicts Mainz Biomed Q1 Earnings

Mainz Biomed (NASDAQ:MYNZ) – Equities research analysts at HC Wainwright issued their Q1 2025 earnings estimates for shares of Mainz Biomed in a report released on Monday, November 25th. HC Wainwright analyst Y. Chen anticipates that the company will post earnings per share of ($0.07) for the quarter. HC Wainwright currently has a “Neutral” rating on the stock. The consensus estimate for Mainz Biomed’s current full-year earnings is ($0.88) per share. HC Wainwright also issued estimates for Mainz Biomed’s Q2 2025 earnings at ($0.06) EPS, Q3 2025 earnings at ($0.05) EPS, Q4 2025 earnings at ($0.05) EPS and FY2025 earnings at ($0.23) EPS.

Mainz Biomed Price Performance

Shares of NASDAQ:MYNZ opened at $0.21 on Tuesday. Mainz Biomed has a one year low of $0.19 and a one year high of $1.79. The firm has a 50 day simple moving average of $0.26 and a 200 day simple moving average of $0.40.

Mainz Biomed Company Profile

Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer.